Ignite Creation Date:
2024-05-05 @ 10:46 PM
Last Modification Date:
2024-10-26 @ 10:24 AM
Study NCT ID:
NCT01185366
Status:
TERMINATED
Last Update Posted:
2021-04-28
First Post:
2010-08-18
Brief Title:
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
Everolimus Versus Sunitinib Therapy in Patients With Advanced Non-clear Cell Renal Cell Carcinoma
Status:
TERMINATED
Status Verified Date:
2021-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical research study is to compare the effectiveness of Afinitor everolimus and Sutent sunitinib for the treatment of advanced renal cell carcinoma kidney cancer The safety of each treatment will also be studied
Detailed Description:
The Study Drugs
Everolimus is designed to stop cells from multiplying It may also stop the growth of new blood vessels that help tumor growth which may cause the tumor cells to die
Sunitinib is designed to block pathways that control important events such as the growth of blood vessels that are essential for the growth of cancer
Study Groups and Study Drug Administration
If you are found to be eligible to take part in this study you will be randomly assigned as in the toss of a coin to 1 of 2 groups
If you are assigned to Group 1 you will take 2 everolimus tablets by mouth once every day
If you are assigned to Group 2 you will take sunitinib capsules by mouth every day for 4 weeks followed by 2 weeks off
If you have any side effects from any of the drugs tell the study doctor right away The study doctor may then lower the dose or keep the dose level the same
Every 6 weeks on this study is called a study cycle
If the disease gets worse or you have intolerable side effects while you are on study you will have the chance to receive the study drug that you did not receive at first The dosing and follow-up will be the same as for all participants in that group
Study Visits
On Day 1 of every cycle
You will have a physical exam including measurement of your vital signs
You will be asked about any drugs or treatments you may be receiving
Your performance status will be recorded
Blood about 3 teaspoons and urine will be collected for routine tests and a fasting blood sugar test Blood or urine will also be used for a pregnancy test for women who are able to have children If you are in Group 1 you will have an additional 1 teaspoon of blood drawn to test your cholesterol
On Day 15 and 29 of Cycle 1
Your vital signs and weight will be measured
Blood about 2 teaspoons will be drawn for routine tests If you are in Group 1 an additional 1 teaspoon of blood will be drawn to measure your cholesterol
The Day 15 and Day 29 tests may be done at your local doctors office
On Day 1 of Cycles 2 and 3 and every other cycle after that Day 1 of Cycle 5 7 9 and so on
You will have a CT scan of the chest and a CT scan or MRI of the abdomen to check the status of the disease
Every 4 cycles 24 weeks
If you are in Group 2 you will have an echocardiogram or MUGA scan to check your hearts health
Length of Study
You may continue taking the study drugs for as long as you are benefiting You will be taken off study if the disease gets worse or intolerable side effects occur
End-of-Treatment Visit
If you have stopped taking the study drug because of intolerable side effects the treating physician will make every effort to check the status of the disease before you are taken off of study
Long-Term Follow-up
Once you are no longer on this study the research staff will check up on you about every 6 months This update will consist of a phone call or a review of your medical andor other records You will not have any extra tests procedures or study visits If contacted by phone the call would only last about 5 minutes
This is an investigational study Sunitinib and everolimus are both FDA approved and commercially available for the treatment of advanced kidney cancer
Up to 108 patients will be enrolled in this multicenter trial Up to 108 patients will be enrolled at MD Anderson
Everolimus is designed to stop cells from multiplying It may also stop the growth of new blood vessels that help tumor growth which may cause the tumor cells to die
Sunitinib is designed to block pathways that control important events such as the growth of blood vessels that are essential for the growth of cancer
Study Groups and Study Drug Administration
If you are found to be eligible to take part in this study you will be randomly assigned as in the toss of a coin to 1 of 2 groups
If you are assigned to Group 1 you will take 2 everolimus tablets by mouth once every day
If you are assigned to Group 2 you will take sunitinib capsules by mouth every day for 4 weeks followed by 2 weeks off
If you have any side effects from any of the drugs tell the study doctor right away The study doctor may then lower the dose or keep the dose level the same
Every 6 weeks on this study is called a study cycle
If the disease gets worse or you have intolerable side effects while you are on study you will have the chance to receive the study drug that you did not receive at first The dosing and follow-up will be the same as for all participants in that group
Study Visits
On Day 1 of every cycle
You will have a physical exam including measurement of your vital signs
You will be asked about any drugs or treatments you may be receiving
Your performance status will be recorded
Blood about 3 teaspoons and urine will be collected for routine tests and a fasting blood sugar test Blood or urine will also be used for a pregnancy test for women who are able to have children If you are in Group 1 you will have an additional 1 teaspoon of blood drawn to test your cholesterol
On Day 15 and 29 of Cycle 1
Your vital signs and weight will be measured
Blood about 2 teaspoons will be drawn for routine tests If you are in Group 1 an additional 1 teaspoon of blood will be drawn to measure your cholesterol
The Day 15 and Day 29 tests may be done at your local doctors office
On Day 1 of Cycles 2 and 3 and every other cycle after that Day 1 of Cycle 5 7 9 and so on
You will have a CT scan of the chest and a CT scan or MRI of the abdomen to check the status of the disease
Every 4 cycles 24 weeks
If you are in Group 2 you will have an echocardiogram or MUGA scan to check your hearts health
Length of Study
You may continue taking the study drugs for as long as you are benefiting You will be taken off study if the disease gets worse or intolerable side effects occur
End-of-Treatment Visit
If you have stopped taking the study drug because of intolerable side effects the treating physician will make every effort to check the status of the disease before you are taken off of study
Long-Term Follow-up
Once you are no longer on this study the research staff will check up on you about every 6 months This update will consist of a phone call or a review of your medical andor other records You will not have any extra tests procedures or study visits If contacted by phone the call would only last about 5 minutes
This is an investigational study Sunitinib and everolimus are both FDA approved and commercially available for the treatment of advanced kidney cancer
Up to 108 patients will be enrolled in this multicenter trial Up to 108 patients will be enrolled at MD Anderson
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2012-01789 | REGISTRY | NCI CTRP | None |